Navigation Links
Cumberland Pharmaceuticals And PT. SOHO Industri Pharmasi enter Into Exclusive Licensing Agreement For Caldolor In Indonesia
Date:1/29/2013

arrangement with SOHO, Cumberland has licensed rights for Caldolor to partners in China, South Korea, Malaysia, Dubai, Canada, Australia and New Zealand.

"There is a significant and growing body of research that supports the safety and efficacy of Caldolor," said Marcus Pitt , President, Director and CEO of SOHO Group (a holding company of PT. SOHO Industri Pharmasi). "Due to Caldolor's attributes and strong performance in clinical trials in the United States, we are excited to share this innovative product with physicians and patients throughout Indonesia."

Following regulatory approval, SOHO will use its existing sales force to promote Caldolor throughout Indonesia. The product features analgesic, antipyretic and anti-inflammatory properties and is designed for the treatment of pain and fever, primarily in hospitalized patients who are unable to receive oral therapies. In clinical trials, Caldolor has demonstrated significant reductions in post-operative pain when compared with opioids alone while significantly reducing opioid requirements.

About Caldolor®

Caldolor is indicated for the management of mild to moderate pain and management of moderate to severe pain as an adjunct to opioid analgesics, and for the reduction of fever in adults. It is the first FDA approved intravenous therapy for fever. Caldolor is contraindicated in patients with known hypersensitivity to ibuprofen or other NSAIDs, patients with asthma, urticaria, or allergic type reactions after taking aspirin or other NSAIDs. Caldolor is contraindicated for use during the peri-operative period in the setting of coronary artery bypass graft (CA
'/>"/>

SOURCE Cumberland Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Cumberland Pharmaceuticals Reports First Quarter 2012 Financial Results
2. Cumberland Pharmaceuticals To Present At The 2012 Wells Fargo Securities Healthcare Conference In Boston
3. Cumberland Pharmaceuticals To Announce Second Quarter 2012 Financial Results On August 2, 2012
4. Cumberland Pharmaceuticals Reports Second Quarter 2012 Financial Results
5. Cumberland Pharmaceuticals to Present at the UBS Global Life Sciences Conference in New York
6. Cumberland Pharmaceuticals Reports Third Quarter 2012 Financial Results
7. Cumberland Emerging Technologies Expands Life Sciences Center
8. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
9. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
10. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
11. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... Aug. 27, 2014  Columbia Laboratories, Inc. (Nasdaq: ... of pharmaceutical development, clinical trial manufacturing, and advanced analytical ... that it will participate at the upcoming Rodman & ... be held in New York . ... on September 9, 2014 at the New York Palace ...
(Date:8/27/2014)... NORWALK, Conn. , Aug. 27, 2014  UBM ... , a leading online community for medical imaging professionals, ... Association for Medical Imaging Management,s 2014 Annual Meeting ... the conference coverage: , 11 Principles ... management can lead to greater profitability. , ...
(Date:8/27/2014)... DIEGO , Aug. 27, 2014 Ambit Biosciences (Nasdaq: ... and development of drugs targeting unmet needs in oncology, autoimmune ... Baird 2014 Health Care Conference to be held at The ... on September 3-4, 2014. Alan ... Company and its lead drug candidate, quizartinib, at 1:10 p.m. ...
Breaking Medicine Technology:Diagnostic Imaging Covers Association for Medical Imaging Management (AHRA) 2014 Meeting 2Diagnostic Imaging Covers Association for Medical Imaging Management (AHRA) 2014 Meeting 3Ambit Announces Participation At Baird 2014 Health Care Conference 2
... Oramed Pharmaceuticals, Inc.,(OTCBB: ORMP.OB) ( http://www.oramed.com ), a ... to present at the 8th National Life,Science & Technology ... by Mr. Nadav Kidron, President and CEO of Oramed,on ... p.m. (local time),at the David Intercontinental Hotel in Tel-Aviv, ...
... Patients Demonstrated Improvement With Every-Four-Week Subcutaneous SIMPONI Despite ... , COPENHAGEN, June 9 A new analysis ... moderately to severely active rheumatoid arthritis (RA) who ... agents and received subcutaneous injections of SIMPONI(TM) (golimumab) ...
Cached Medicine Technology:Oramed Pharmaceuticals to Present at the 8th National Life Science & Technology Week ILSI -BIOMED Conference, Israel 2009 2New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients 2New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients 3New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients 4New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients 5New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients 6New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients 7New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients 8New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients 9New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients 10
(Date:8/27/2014)... The American Brain Tumor Association is ... Research Fellowships and 2014-2015 Discovery Grant Awards. Through the ... the field with talented, bright young investigators who have ... effects, diagnosis and treatment of brain tumors. This year’s ... the potential to advance the understanding and treatment of ...
(Date:8/27/2014)... to help regulate the blood,s iron supply shows promise as ... results from the first human study of the ... the Journal of the American Society of Hematology ... cells are in short supply or do not function properly. ... enough oxygen, since there are fewer red blood cells to ...
(Date:8/27/2014)... trial participation in the largest ongoing observational study of ... representative of the larger patient base, according to a ... Udell. The study authors call into question the general ... suggest the use of broader enrollment criteria and existing ... that clinical trials can be tremendously expensive and a ...
(Date:8/27/2014)... University,s Center for Leadership in Disability (CLD) has ... and Child Health Bureau of the Health Resources ... Autism Plan for Georgia, aimed at improving services ... , In preparing for this project, CLD worked ... stakeholders from across Georgia. The resulting plan addresses ...
(Date:8/27/2014)... August 27, 2014 Jaha was founded with ... Jaha invested in creating the industry’s most affordable fitness tracker ... that no other apps possess. Jaha plans to ... differentiates in three simple steps: locate, challenge and motivate. ... Aug 26, 2014 to garner support and to raise awareness ...
Breaking Medicine News(10 mins):Health News:American Brain Tumor Association Awards New Research Grants to Best and Brightest Investigators 2Health News:American Brain Tumor Association Awards New Research Grants to Best and Brightest Investigators 3Health News:Drug represents first potential treatment for common anemia 2Health News:Participants of cardiac clinic trials do not represent real world patients, study finds 2Health News:Jaha, Inc. The Most Affordable Fitness Band in the Market Released on Kickstarter 2
... study has shown that children, who are exposed to smoke, ... are likely to have impaired vitamin C levels. Earlier studies ... study, which involved 520 children aged 2 to 12 years, ... have plasma ascorbate concentrations that were lower by an average ...
... the recent past have argued about the implications of Hormone ... menopausal symptoms. A new study, however, has gone further to ... risk of developing breast cancer// if they consumed alcoholic beverages. ... alcohol consumption pattern and on whether they were on HRT ...
... immediately prior to menopause beginning with normal, biological, and ... menstrual periods, is a time of increased vulnerability to ... disorders. Earlier studies have shown that women who experienced ... two to three times more likely to have had ...
... A recent study called 'HERS' conducted by researchers of the ... women, has found that Hormone Replacement Therapy (HRT) may be ... go on to develop diabetes as well. ,The study ... did not or had "impaired fasting glucose" - a ...
... is almost an established truth now. However, many of us ... of pizza could do to our overall health. A recent ... //for Science in the Public Interest (CSPI), which involved 36 ... and looked at dietary information provided by four famous pizza ...
... in the Institute of Preventive Medicine in Copenhagen suggests ... dementia and Alzheimer's disease. Scientists, who found// that people ... two times less likely to develop dementia, said that ... in wine which reduce the occurrence of dementia. This ...
Cached Medicine News:Health News:Women on HRT should avoid alcohol 2Health News:Depressed women show signs of earlier onset of Perimenopause 2Health News:Pizza is bad for health. But, do you know how bad? 2
... Littmann Electronic Stethoscope Model 4100WS features amplification ... allowing you to reduce ambient noise by ... critical body sounds. Three frequency modes are ... other body sounds: Bell (20-200 Hz), Diaphragm ...
... the best EMR value for many medical ... Charting Plus™ relies heavily on a user-friendly ... improve documentation quality and increase productivity in ... specific to your medical specialty. Each program ...
... is a portable, battery-powered bone growth stimulator used ... device is worn for 30 minutes each day ... fusion site. The device uses a unique technology, ... energy signal that is very potent in its ...
... is a multi-site, implantable biventricular ... and two ventricular ports for ... (AF) who have undergone an ... have NYHA Class II or ...
Medicine Products: